Aruna D Pradhan
Overview
Explore the profile of Aruna D Pradhan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
2785
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nordestgaard A, Pradhan A, Everett B, MacFadyen J, Bhatt D, Visseren F, et al.
Eur Heart J
. 2025 Feb;
PMID: 39950981
Background And Aims: Guidelines focus on individuals with triglycerides between 2.3 and 5.6 mmol/L (200 and 499 mg/dL). The hypotheses that triglycerides across the full biological range and within this...
2.
Qian F, Guo Y, Li C, Liu Y, Luttmann-Gibson H, Gomelskaya N, et al.
Cardiovasc Diabetol
. 2024 Nov;
23(1):393.
PMID: 39488682
Background: Dysglycemia and insulin resistance increase type 2 diabetes (T2D) and cardiovascular disease (CVD) risk, yet associations with specific glucose-insulin homeostatic biomarkers have been inconsistent. Vitamin D and marine omega-3...
3.
Burger P, Pradhan A, Dorresteijn J, Koudstaal S, Teraa M, de Borst G, et al.
Am J Cardiol
. 2023 May;
197:13-23.
PMID: 37218417
Anti-inflammatory drugs reduce the risk of cardiovascular events in patients with coronary artery disease (CAD), but less is known about the relation between inflammation and outcomes in patients with cerebrovascular...
4.
Malick W, Waksman O, Do R, Koenig W, Pradhan A, Stroes E, et al.
J Am Coll Cardiol
. 2023 Apr;
81(16):1646-1658.
PMID: 37076219
Triglyceride-rich lipoproteins (TRLs) are a source of residual risk in patients with atherosclerotic cardiovascular disease, and are indirectly correlated with triglyceride (TG) levels. Previous clinical trials studying TG-lowering therapies have...
5.
Taqueti V, Shah A, Everett B, Pradhan A, Piazza G, Bibbo C, et al.
JACC Basic Transl Sci
. 2023 Mar;
8(2):141-151.
PMID: 36908662
Inflammation is a key determinant of cardiovascular outcomes, but its role in heart failure is uncertain. In patients with cardiometabolic disease enrolled in the prospective, multicenter ancillary study of CIRT...
6.
Ridker P, Bhatt D, Pradhan A, Glynn R, MacFadyen J, Nissen S
Lancet
. 2023 Mar;
401(10384):1293-1301.
PMID: 36893777
Background: Inflammation and hyperlipidaemia jointly contribute to atherothrombotic disease. However, when people are treated with intensive statin therapy, the relative contributions of inflammation and hyperlipidaemia to the risk of future...
7.
Bartoli-Leonard F, Turner M, Zimmer J, Chapurlat R, Pham T, Aikawa M, et al.
J Lipid Res
. 2022 Jun;
63(8):100242.
PMID: 35724702
Elevated circulating lipoprotein (a) [Lp(a)] is associated with an increased risk of first and recurrent cardiovascular events; however, the effect of baseline Lp(a) levels on long-term outcomes in an elderly...
8.
Levin M, Zuber V, Walker V, Klarin D, Lynch J, Malik R, et al.
Circulation
. 2021 Jun;
144(5):353-364.
PMID: 34139859
Background: Lipoprotein-related traits have been consistently identified as risk factors for atherosclerotic cardiovascular disease, largely on the basis of studies of coronary artery disease (CAD). The relative contributions of specific...
9.
Aday A, Duran E, Van Denburgh M, Kim E, Christen W, Manson J, et al.
Arterioscler Thromb Vasc Biol
. 2021 May;
41(7):2215-2224.
PMID: 34039021
[Figure: see text].
10.